Abstract 294P
Background
More than a third of small pelvis cancer cases in Uzbekistan are diagnosed in the late stages, where the main goal of medical interventions is to increase life expectancy with maximum maintenance of the quality of life. Opioid prescription and opiophobia in medical personnel make it harder to control pain in this group of patients, decreasing the quality of their life.
Methods
34 patients with locally advanced tumors of small pelvis (17 rectal cancer, 11 cervical cancer, 6 prostate cancer) with pain syndrome by visual analog scale (VAS) 8-10 were selected as the study group. Patients were treated in National cancer center of Uzbekistan in 2017-2020. Epidural catheter was placed in V4-5. Solution of bupivacaine 2.5% 20 ml with 1% of morphine injected at primary point. Then, 5 ml of bupivacaine 2.5% every 6 hours, 1 ml of 1% morphine every 12 hrs. Mean period of catheter placement was 23,6 days (7-36). in order to decrease the possibility of infection wide spectrum of antibiotics and wound dressing were administered. Control group included 34 patients with locally advanced tumors of small pelvis (20 rectal cancer, 12 cervical cancer, 2 prostate cancer) with pain syndrome by visual analog scale (VAS) 8-10. They underwent standard WHO pain ladder therapy morphine 1%-1 ml every 4-6 hrs ± ketorolac 30 mg – 1 ml.
Results
Withing the 20 minutes of administering, median pain syndrome by VAS was 0.78 (0-4). 6 (17.6%) patients admitted headache, 3 dizziness (8.8%). 2 patients admitted 1st grade nausea (5.9%). Constipation was not admitted in the main group. Drowsiness was admitted in 7 patients (20.6%). All of the symptoms disappeared within the 7 days period of hospitalization. In control group, the mean pain syndrome was 4.6 (0-7) by VAS. Drowsiness effect was observed in 27 patients (79.4), however, 21 (61.8%) cases this effect regressed in 7-day period. In 3-months observation period, 11 (32.6) patients from second group had complains on constipation which was resolved with laxatives and enemas.
Conclusions
Analgesia with usage of long-term epidural catheter placement allowed to achieve better pain control, lower opioid usage and avoid severe complications in patients with severe chronic pain syndrome of small pelvis tumors.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center of Uzbekistan.
Funding
National Cancer Center of Uzbekistan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session